Literature DB >> 21855555

On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.

J M Wierońska1, K Stachowicz, P Brański, A Pałucha-Poniewiera, A Pilc.   

Abstract

Earlier studies have demonstrated that the agonists of the mGlu(2/3) receptors produced anxiolytic actions after peripheral administration. However, the mechanism of their action is still not clear. Therefore the aim of the present study was to specify the role of the GABAergic and serotonergic system in the mechanism of the anxiolytic activity of group II mGlu receptor activators by using the stress induced hyperthermia test (SIH) in singly housed mice. We used an orthosteric mGlu(2/3) receptor agonist, LY379268, which induced anti-hyperthermic efficacy in the doses of 1-5mg/kg (73% of inhibition after a highest dose). The effect of the second ligand used, a mGlu(2) receptor positive modulator (PAM), LY487379, was observed in a dose range of 0.5-5mg/kg and reached 53% of the inhibition. The blockade of GABAergic system by GABA(A) receptor antagonist flumazenil (10mg/kg) or GABA(B) receptor antagonist CGP55845 (10mg/kg), and the blockade of serotonergic system by 5-HT(1A) receptor antagonist WAY100635 (0.1 and 1mg/kg) or 5-HT(2A/2C) receptor antagonist ritanserin (0.5mg/kg) had no influence on the anti-hyperthermic effect induced by effective dose of LY379268. However, the action of the effective dose of LY487379 was enhanced when co-administered with flumazenil, WAY100635 (0.1mg/kg) and ritanserin. Similar results were observed for the subeffective dose of LY379268 (0.5mg/kg). WAY100635 in a dose of 1mg/kg did not induce any enhancing effect on the activity of compounds. Therefore, it seems that the antagonism towards GABA(A) receptors, presynaptic 5-HT(1A) and postsynaptic 5-HT(2A/2C) receptors is responsible for the phenomenon. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855555     DOI: 10.1016/j.neuropharm.2011.07.042

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

2.  The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety.

Authors:  Vasilios Grivas; Athina Markou; Nikolaos Pitsikas
Journal:  Eur J Pharmacol       Date:  2013-06-11       Impact factor: 4.432

Review 3.  Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.

Authors:  Deborah J Luessen; P Jeffrey Conn
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

4.  The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.

Authors:  Joanna M Wierońska; Francine C Acher; Anna Sławińska; Piotr Gruca; Magdalena Lasoń-Tyburkiewicz; Mariusz Papp; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2013-03-10       Impact factor: 4.530

5.  Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage.

Authors:  Marta Motolese; Federica Mastroiacovo; Milena Cannella; Domenico Bucci; Anderson Gaglione; Barbara Riozzi; Robert Lütjens; Sonia M Poli; Sylvain Celanire; Valeria Bruno; Giuseppe Battaglia; Ferdinando Nicoletti
Journal:  Mol Brain       Date:  2015-10-24       Impact factor: 4.041

6.  Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.

Authors:  Raveendra-Panickar Dhanya; Douglas J Sheffler; Russell Dahl; Melinda Davis; Pooi San Lee; Li Yang; Hilary Highfield Nickols; Hyekyung P Cho; Layton H Smith; Manoranjan S D'Souza; P Jeffrey Conn; Andre Der-Avakian; Athina Markou; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2014-05-09       Impact factor: 7.446

Review 7.  The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.

Authors:  Daniel Peterlik; Peter J Flor; Nicole Uschold-Schmidt
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.